Warby Parker Inc.

WRBY
About the company

Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services.

Country: United StatesPrice: $27.44Market Cap: $3.4B

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

3 / 12

NEUTRAL / FAIL

Median fair value

$0.81

-97.0% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

All 13 investors flag WRBY's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1881 (Top 60.7%)NEUTRALFAILFAILFAILFAILFAILFAILFAILPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-3287.7%-17050.0%N/AN/AN/AN/A-373.9%-8475.0%N/AN/A-153.4%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✗ 28▾

      All 13 investors flag WRBY's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio9.3x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-0.2%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.2%, ROC=-5.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS2744.0x
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)31.0x
      ✗Dreman< 8x
      Price / Book Value per Share9.3x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessP/E=2744.0x, OE Yield=-0.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldP/E=2744.0x, FCF Yield=1.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/E=2744.0x, P/B=9.3x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share78.5x
      ✗Ackman<= 25
      Price vs. Trailing Low166% of trailing low ($16.51)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization+0.22%; #3133/6340 (top 49.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.1182; #4648/6449 (top 72.1%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS2744.0x
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share9.33x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.2740; #3448/5247 (top 65.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization+0.62%; #2446/4519 (top 54.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+31.80%; #979/6202 (top 15.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Valuation models0% pass✗ 5▾

      WRBY overvalued: all 5 models price fair value below $27.44 (median $0.81)

      Graham fair value$0.81
      ✗Graham-3287.7% margin vs $27.44
      Buffett fair value$0.16
      ✗Buffett-17050.0% margin vs $27.44
      Munger fair value$5.79
      ✗Munger-373.9% margin vs $27.44
      Pabrai fair value$0.32
      ✗Pabrai-8475.0% margin vs $27.44
      Ackman fair value$10.83
      ✗Ackman-153.4% margin vs $27.44
    • Profitability6% pass✓ 8✗ 27▾

      15 of 16 flag WRBY's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-23.1%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-0.6% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$1.6M
      ✓BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE1.9%
      ✗Lynch> 15%
      EBIT / Enterprise Value-0.2%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.2%, ROC=-5.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets0.23%
      ✓PiotroskiROA > 0
      ROA Change YoY-3.01% -> 0.23% (delta: +3.24%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=15.37%, ROA=0.23%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY55.3% -> 54.0%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue1.1%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity1.9%
      ✗Dreman> 12%
      Margin of SafetyP/E=2744.0x, P/B=9.3x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-8.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue0.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity1.9%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-10.7% (2023) -> -0.6% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 54.5% -> 54.0%, operating margin -10.7% -> -0.6%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization+0.22%; #3133/6340 (top 49.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+64.60%; #406/3702 (top 11.0%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity+1.85%; #2772/5226 (top 53.0%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1191; #3691/5884 (top 62.7%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 12 FAIL · 3 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (2/9)✗LynchFAIL (1/7)✗GreenblattRank #1881•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag WRBY's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.26
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-16.4x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Growth13% pass✓ 4✗ 9▾

      7 of 8 flag WRBY's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 1.5% vs Rev: 9.9%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth13.0%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 54.5% -> 54.0%, operating margin -10.7% -> -0.6%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR17.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag WRBY's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio2.26
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-5.2%
      ✗Greenblatt> 25%
      Current Ratio Change YoY2.50 -> 2.35
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY1.14x -> 1.21x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.26
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Cash Flow50% pass✓ 6✗ 6▾

      5 of 10 pass — Lynch, Dreman, Pabrai +2 more object

      Free Cash Flow Proxy$1.6M
      ✓BuffettPositive and growing
      FCF Positive and Growing$21.3M
      ✗LynchPositive and growing
      Operating Cash Flow$110.8M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=15.37%, ROA=0.23%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)31.0x
      ✗Dreman< 8x
      P/E or FCF YieldP/E=2744.0x, FCF Yield=1.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive4/7 years FCF positive
      ✓MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap0.6%
      ✗Ackman>= 4%
      Price / FCF per Share78.5x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency6/7 years positive
      ✓SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$21.3M
      ✓Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization+0.62%; #2446/4519 (top 54.1%)
      ✗OshaughnessyTop 10% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Mid Cap($3.4B)
    Revenue: $871.9M+13.0% YoY
    Net Income: $1.6M+108.0% YoY

    Financial Snapshot

    Operating Margin-0.6%
    Return on Equity0.4%
    Debt / Equity--
    Current Ratio2.35
    EPS (Diluted)$0.01
    Shares Retired−3.9% / −6.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 3.9% of shares last year, 6.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-02-26
    FY 2024
    Sources
    • 10-K · 2025-02-27
    FY 2023
    Sources
    • 10-K · 2024-02-29
    FY 2022
    Sources
    • 10-K · 2023-02-28
    FY 2021
    Sources
    • 10-K · 2022-03-18
    Market Cap$3.4Bcurrent------$3.2Best.$3.3Best.$1.5Best.$1.9Best.$2.6Best.
    Revenue$934.7M↑10%$244.7M↑10%$235.5M↑10%$242.4M↑8%$871.9M↑13%$771.3M↑15%$669.8M↑12%$598.1M↑11%$540.8M
    Operating Income$1.5M↑119%$3.6M$3.2M↑170%$1.7M↓33%-$5.3M↑82%-$30.1M↑58%-$72.0M↑35%-$111.2M↑23%-$143.7M
    Net Income$7.5M↑942%$5.6M↓5%$4.6M↑365%$3.2M↓8%$1.6M↑108%-$20.4M↑68%-$63.2M↑43%-$110.4M↑23%-$144.3M
    EPS (Diluted)--$0.04↓20%$0.04↑500%$0.03$0.01↑106%$-0.17↑69%$-0.54↑44%$-0.96↑57%$-2.21
    Gross Margin54.7%↑1%54.4%↑1%57.9%↑9%54.0%↓4%54.0%↓2%55.3%↑1%54.5%↓4%57.0%↓3%58.8%
    Operating Margin0.2%↑118%1.5%↓10%1.3%↑164%0.7%↓38%-0.6%↑84%-3.9%↑64%-10.7%↑42%-18.6%↑30%-26.6%
    ROE1.9%↑855%———0.4%↑107%-6.0%↑71%-20.9%↑46%-38.5%↑24%-50.4%
    Total Debt------------------
    Shareholders' Equity$403.3M↑9%$403.3M↑9%$392.0M↑8%$375.8M↑6%$367.7M↑8%$340.1M↑13%$301.8M↑5%$286.6M$286.0M
    Current Ratio2.26↓13%2.26↓13%2.27↓11%2.33↓13%2.35↓6%2.50↑6%2.35↑3%2.27↓18%2.78
    Debt / Equity—————————
    Operating Cash Flow$102.1M↓5%$24.7M↑38%$29.6M↓26%$24.5M↓17%$110.8M↑12%$98.7M↑62%$61.0M↑488%$10.4M↑132%-$32.0M
    Free Cash Flow$21.3M↓44%-$2.0M↓30%$6.8M↓72%$8.4M↓37%$43.7M↑26%$34.7M↑374%$7.3M↑115%-$49.8M↑38%-$80.5M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    WRBY vs Peers — Financial Grading

    Revenue$871.9MMedian
    Net Income$1.6MBottom 25%
    ROE0.4%Bottom 25%
    D/E—
    Op. Margin-0.6%Bottom 25%
    Curr. Ratio2.35Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11